A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)

Background: Most non-small cell lung cancers occur in elderly and frequently comorbid patients. Therefore, it is necessary to evaluate the efficacy of biomodulatory active therapy regimen, concertedly interfering with tumor-associated homeostatic pathways to achieve tumor control paralleled by modes...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Daniel Heudobler, Christian Schulz, Jürgen R. Fischer, Peter Staib, Thomas Wehler, Thomas Südhoff, Thomas Schichtl, Jochen Wilke, Joachim Hahn, Florian Lüke, Martin Vogelhuber, Sebastian Klobuch, Tobias Pukrop, Wolfgang Herr, Swantje Held, Kristine Beckers, Gauthier Bouche, Albrecht Reichle
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-03-01
coleção:	Frontiers in Pharmacology
Assuntos:	biomodulation anakoinosis NSCLC checkpoint inhibition pioglitazone nivolumab
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2021.599598/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!